1
|
Drozd C, Curtit E, Jacquinot Q, Marquine C, Mansi L, Chaigneau L, Dobi E, Viot J, Meynard G, Paillard MJ, Goujon M, Roux P, Vernerey D, Gillet V, Bourdin H, Galli S, Meneveau N, Mougin F. A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study. BMC Cancer 2023; 23:449. [PMID: 37198562 DOI: 10.1186/s12885-023-10902-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 04/28/2023] [Indexed: 05/19/2023] Open
Abstract
BACKGROUND Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in breast cancer patients. Sleep medications treat symptoms but are ineffective to cure insomnia. Other approaches such as cognitive behavioral therapy for insomnia, relaxation through yoga and mindfulness are often not available for patients and are complex to implement. An aerobic exercise program could be a promising treatment and a feasible option for insomnia management in breast cancer patients, but few studies have investigated the effects of such a program on insomnia. METHODS This multicenter, randomized clinical trial evaluate the effectiveness of a moderate to high intensity physical activity program (45 min, 3 times per week), lasting 12 weeks, in minimizing insomnia, sleep disturbances, anxiety/depression, fatigue, and pain, and in enhancing cardiorespiratory fitness. Patients with breast cancer be recruited from six hospitals in France and randomly allocated to either the "training" or the "control" group. Baseline assessments include questionnaires [Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index questionnaire (PSQI), Hospital Anxiety Depression Scale (HADS), Epworth Sleepiness Scale (ESS)], home polysomnography (PSG), and 7-day actigraphy coupled with completion of a sleep diary. Assessments are repeated at the end of training program and at six-month follow-up. DISCUSSION This clinical trial will provide additional evidence regarding the effectiveness of physical exercise in minimizing insomnia during and after chemotherapy. If shown to be effective, exercise intervention programs will be welcome addition to the standard program of care offered to patients with breast cancer receiving chemotherapy. TRIAL REGISTRATION National Clinical Trials Number (NCT04867096).
Collapse
Affiliation(s)
- Chloé Drozd
- Sports Science Faculty, University of Franche-Comté, Besançon, 25000, France.
- Research Unit EA3920, University of Franche-Comté, Besançon, 25000, France.
- Sleep Medicine Center, Ellipse, Besançon, 25000, France.
| | - Elsa Curtit
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
- INSERM U1098 RIGHT, University of Franche-Comté, Besançon, France
| | - Quentin Jacquinot
- Research Unit EA3920, University of Franche-Comté, Besançon, 25000, France
- Regional Federative Cancer Institute of Franche-Comté, Besançon, France
| | - Charlène Marquine
- Sports Science Faculty, University of Franche-Comté, Besançon, 25000, France
| | - Laura Mansi
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
- INSERM U1098 RIGHT, University of Franche-Comté, Besançon, France
| | - Loïc Chaigneau
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
| | - Erion Dobi
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
| | - Julien Viot
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
| | - Guillaume Meynard
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
| | | | - Morgan Goujon
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
| | - Pauline Roux
- Department of Physiology-Functional Explorations, University Hospital, Besançon, 25000, France
| | - Dewi Vernerey
- Methodology and Quality of Life Unit, UMR 1098, University Hospital, Besançon, 25000, France
| | | | - Hubert Bourdin
- Research Unit EA481, Unit of Sleep Disorder, University of Franche-Comté, Besançon, 25000, France
| | - Silvio Galli
- Department of Neurology, University Hospital, Besançon, 25000, France
| | - Nathalie Meneveau
- Department of Medical Oncology, University Hospital, Besançon, 25000, France
| | - Fabienne Mougin
- Sports Science Faculty, University of Franche-Comté, Besançon, 25000, France
- Research Unit EA3920, University of Franche-Comté, Besançon, 25000, France
| |
Collapse
|
2
|
Chaigneau L, Jary M, Nerich V, Hervieu A, Aubry S, Charon Barra C, Meynard G, Neumann F, Kalbacher E, Isambert N. Real-World Experience of efficacy and safety of trabectedin in patients with soft tissue sarcoma: a bicentric retrospective analysis. Oncology 2022; 100:633-644. [DOI: 10.1159/000527602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 09/23/2022] [Indexed: 11/19/2022]
Abstract
Introduction: Soft tissue sarcomas (STS) are a rare and heterogenous group of tumors, with poor prognostic, judging from their frequency to relapse. Few drugs are available after the conventional first line regimen. Since 2007, trabectedin got approval after failure of anthracyclines and ifosfamide, for advanced or metastatic STS. This led to a FDA approval in 2015, but real-world evidence are still required, complementary to the pivotal phase II and III trials.
Methods: One hundred twenty-six patients with STS, treated by trabectedin between 2002 and 2019 were analysed in this retrospective study, in two French centers. The effects of trabectedin on survival, response, and toxicity, were described. All patients were tested for toxicities, and efficacy was assessed in patients exposed to at least 2 cycles of trabectedin.
Results: Three median cycles were administered per patient (1-79). Among the 113 patients analysed for efficacy, the median progression free survival was 3.0 months [CI95%: 2.3 – 4.8], with an overall survival of 12.3 months [CI95%: 10.2 – 16.9]. The rate of disease control was 46% at the end of treatment. Myxoid liposarcoma (n = 11) was the histology subtype that benefited most from this chemotherapy with median progression free survival and overall survival of 13.3 months [CI95%: 2.3 – 18.7] and 27.8 months [CI95%: 3.2 – 64.7], respectively. Adverse events were manageable.
Discussion and Conclusion: Efficacy of trabectedin is confirmed in terms of clinical benefit and low toxicity, especially for myxoid liposarcoma. Combinatory regimen are under clinical trials to optimize the place of this chemotherapy.
Collapse
|
3
|
Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. Front Cardiovasc Med 2022; 9:1000846. [PMID: 36211552 PMCID: PMC9537598 DOI: 10.3389/fcvm.2022.1000846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 09/05/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective supportive therapy in the management of side effects, but the cardioprotective effects of exercise are still unclear.ObjectivesThe primary aim of this study was to test whether trastuzumab-induced cardiotoxicity [left ventricular ejection fraction (LVEF) under 50%, or an absolute drop in LVEF of 10%] was reduced after a supervised exercise program of 3 months in patients with HER2-positive breast cancer. Secondary endpoints were to evaluate (i) cardiotoxicity rates using other criteria, (ii) cardiac parameters, (iii) cardiorespiratory fitness and (iv) whether a change in LVEF influences the cardiorespiratory fitness.Methods89 women were randomized to receive adjuvant trastuzumab in combination with a training program (training group: TG; n = 46) or trastuzumab alone (control group: CG; n = 43). The primary and secondary endpoints were evaluated at the end of the supervised exercise program of 3 months (T3).ResultsAfter exercise program, 90.5 % of TG patients and 81.8% of CG patients did not exhibit cardiotoxicity. Furthermore, whatever the used criterion, percentage of patients without cardiotoxicity were greater in TG (97.6 and 100% respectively) than in CG (90.9 and 93.9% respectively). LVEF and GLS values remained stable in both groups without any difference between the groups. In contrast, at T3, peak VO2 (+2.6 mL.min−1.kg−1; 95%CI, 1.8 to 3.4) and maximal power (+21.3 W; 95%CI, 17.3 to 25.3) increased significantly in TG, whereas they were unchanged in CG (peak VO2: +0.2 mL.min−1.kg−1; 95%CI, −0.5 to 0.9 and maximal power: +0.7 W, 95%CI, −3.6 to 5.1) compared to values measured at T0. No correlation between LVEF changes and peak VO2 or maximal power was observed.ConclusionA 12-week supervised exercise regimen was safe and improved the cardiopulmonary fitness in particular peak VO2, in HER2-positive BC patients treated with adjuvant trastuzumab therapy. The study is under powered to come to any conclusion regarding the effect on cardiotoxicity.Clinical trial registrationwww.ClinicalTrials.gov, identifier: NCT02433067.
Collapse
Affiliation(s)
- Quentin Jacquinot
- Regional Federative Cancer Institute of Franche-Comté, Besançon, France
- Research Unit EA3920, University of Franche-Comté, Besançon, France
- *Correspondence: Quentin Jacquinot
| | - Nathalie Meneveau
- Department of Medical Oncology, University Hospital, Besançon, France
| | - Antoine Falcoz
- UMR 1098, Methodology and Quality of Life Unit in Oncology, University Hospital, Besançon, France
| | - Malika Bouhaddi
- Research Unit EA3920, University of Franche-Comté, Besançon, France
- Physiology-Functional Explorations, University Hospital, Besançon, France
| | - Pauline Roux
- Physiology-Functional Explorations, University Hospital, Besançon, France
| | - Bruno Degano
- Heart-Lung Unit, Department of Physiology-Functional Explorations, University Hospital, Grenoble, France
| | - Marion Chatot
- Department of Cardiology, University Hospital, Besançon, France
| | - Elsa Curtit
- Department of Medical Oncology, University Hospital, Besançon, France
- INSERM UMR 1098, Host-Graft-Tumor Interaction, Cell and Gene Engineering, University of Franche-Comté, Besançon, France
| | - Laura Mansi
- Department of Medical Oncology, University Hospital, Besançon, France
- INSERM UMR 1098, Host-Graft-Tumor Interaction, Cell and Gene Engineering, University of Franche-Comté, Besançon, France
| | | | - Fernando Bazan
- Department of Medical Oncology, University Hospital, Besançon, France
| | - Loïc Chaigneau
- Department of Medical Oncology, University Hospital, Besançon, France
| | - Erion Dobi
- Department of Medical Oncology, University Hospital, Besançon, France
| | - Guillaume Meynard
- Department of Medical Oncology, University Hospital, Besançon, France
| | - Dewi Vernerey
- UMR 1098, Methodology and Quality of Life Unit in Oncology, University Hospital, Besançon, France
| | | | - Fabienne Mougin
- Research Unit EA3920, University of Franche-Comté, Besançon, France
- Sports Science Faculty, University of Franche-Comté, Besançon, France
| |
Collapse
|
4
|
Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, Vernerey D, Meurisse A, Kim S, Borg C, Mansi L. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study. Front Oncol 2022; 12:957580. [PMID: 35928870 PMCID: PMC9343837 DOI: 10.3389/fonc.2022.957580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Accepted: 06/23/2022] [Indexed: 11/18/2022] Open
Abstract
Background There is a strong rational of using anti–programmed cell death protein-1 and its ligand (anti–PD-1/L1) antibodies in human papillomavirus (HPV)–induced cancers. However, anti–PD-1/L1 as monotherapy induces a limited number of objective responses. The development of novel combinations in order to improve the clinical efficacy of an anti–PD-1/L1 is therefore of interest. Combining anti–PD-1/L1 therapy with an antitumor vaccine seems promising in HPV-positive (+) cancers. UCPVax is a therapeutic cancer vaccine composed of two separate peptides derived from telomerase (hTERT, human telomerase reverse transcriptase). UCPVax is being evaluated in a multicenter phase I/II study in NSCLC (non–small cell lung cancer) and has demonstrated to be safe and immunogenic. The aim of the VolATIL study is to evaluate the combination of atezolizumab (an anti-PD-L1) and UCPVax vaccine in a multicenter phase II study in patients with HPV+ cancers. Methods Patients with HPV+ cancer (anal canal, head and neck, and cervical or vulvar), at locally advanced or metastatic stage, and refractory to at least one line of systemic chemotherapy are eligible. The primary end point is the objective response rate (ORR) at 4 months. Patients will receive atezolizumab every 3 weeks at a fixed dose of 1,200 mg in combination with the UCPVax vaccine at 1 mg subcutaneously. Discussion Anti-cancer vaccines can restore cancer-immunity via the expansion and activation of tumor-specific T cells in patients lacking pre-existing anti-tumor responses. Moreover, preclinical data showed that specific TH1 CD4 T cells sustain the quality and homing of an antigen-specific CD8+ T-cell immunity. In previous clinical studies, the induction of anti-hTERT immunity was significantly correlated to survival in patients with advanced squamous anal cell carcinoma. Thus, there is a strong rational to combine an anti-cancer hTERT vaccine and an immune checkpoint inhibitor to activate and promote antitumor T-cell immunity. This pivotal proof of concept study will evaluate the efficacy and safety of the combination of a telomerase-based TH1 inducing vaccine (UCPVax) and an anti–PD-L1 (atezolizumab) immunotherapy in HPV+ cancers, as well as confirming their synergic mechanism, and settling the basis for a new combination for future clinical trials. Clinical Trial Registration https://www.clinicaltrials.gov/, identifier NCT03946358.
Collapse
Affiliation(s)
- Magali Rebucci-Peixoto
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
- Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire, Besançon, France
- *Correspondence: Magali Rebucci-Peixoto,
| | - Angélique Vienot
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
- Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire, Besançon, France
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, Besançon, France
| | - Olivier Adotevi
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
- Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire, Besançon, France
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, Besançon, France
| | - Marion Jacquin
- Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire, Besançon, France
- Cancéropôle Est, Strasbourg, France
| | | | | | - Benoit You
- Department of Oncology, Hospices Civils de Lyon, Lyon, France
| | - Tristan Maurina
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
| | - Elsa Kalbacher
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
| | - Fernando Bazan
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
| | - Guillaume Meynard
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
| | - Anne-Laure Clairet
- Department of Pharmacy, University Hospital of Besançon, Besançon, France
| | | | - Laurie Spehner
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, Besançon, France
| | - Adeline Bouard
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, Besançon, France
| | - Dewi Vernerey
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
- Methodology and Quality of Life in Oncology Unit, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Aurélia Meurisse
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
- Methodology and Quality of Life in Oncology Unit, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Stefano Kim
- Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire, Besançon, France
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, Besançon, France
- Department of Oncology, Sanatorio Allende, Cordoba, Argentina
| | - Christophe Borg
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
- Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire, Besançon, France
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, Besançon, France
| | - Laura Mansi
- Department of Oncology, Centre Hospitalier Universitaire, Besançon, France
| |
Collapse
|
5
|
Gassian N, Paget-Bailly S, Djoumakh OEK, Mansi L, Dobi E, Bazan F, Curtit E, Chaigneau L, Meneveau N, Paillard MJ, Selmani Z, Viot J, Borg C, Meynard G. HERibuline: Eribulin mesylate and Trastuzumab in pretreated HER2-positive advanced breast cancer—A report of region’s practice. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e13020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13020 Background: Until 2020, in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), the two first lines of metastatic treatment were well defined but after, many options were possible, most often combining targeted therapy plus chemotherapy. Eribulin mesylate is indicated for the treatment of patients with ABC previously treated by anthracycline and taxane regimens in the advanced setting. Here, we present the results of eribuline and trastuzumab (E/T) combination in HER2-positive ABC previously treated. Methods: Patients with HER2-positive ABC treated with the E/T combination from our region cancer institute were included in this retrospective study. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR) and safety. Results: Between November 2013 and July 2019, a total of 34 consecutive patients with HER2-positive ABC were included. The median number of previous lines for advanced setting was 4 (range 2-7). Patients treated by taxanes and anthracyclines represented 91% and 47% respectively; 50%, 79% and 62% were previously treated with pertuzumab, trastuzumab emtansine and lapatinib respectively. After a median follow up of 24.8 months, median PFS was 6.2 months (95% CI [3.35-7.13]) and median OS was 12.6 months (95% CI [7.13-18.56]). The ORR and CBR were 38% and 53%, respectively. No unexpected adverse event was observed. The most frequent grade 3-4 toxicity was hematologic (44.1%). Conclusions: Recently, new therapies have revolutionized the management of HER2-positive ABC and patients benefit from a prolonged overall survival associated with a maintained performance status. However, in pretreated and advanced metastatic setting, there are few scientific evidence to guide the choice of treatments. A combination of E/T could be an effective option in patients with good performance status and willing to receive treatment.
Collapse
Affiliation(s)
| | - Sophie Paget-Bailly
- Methodological and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital, Besançon, France
| | | | - Laura Mansi
- Department of Medical Onclogy, Besançon, France
| | | | | | - Elsa Curtit
- Institut Regional du Cancer en Franche-Comté-University Hospital, Besançon, France
| | - Loic Chaigneau
- Institut Regional du Cancer en Franche-Comté-University Hospital, Besançon, France
| | - Nathalie Meneveau
- Institut Regional du Cancer en Franche-Comté-University Hospital, Besançon, France
| | | | | | - Julien Viot
- Department of Medical Oncology, University Hospital of Besançon, Besançon, France
| | | | - Guillaume Meynard
- Service d'Oncologie Médicale, CHU Jean Minjoz Besançon, Besançon, France
| |
Collapse
|
6
|
Braunstein C, Sirveaux F, Kalbacher E, Aubry S, Delroeux D, Hubert P, Marie B, Meynard G, Mihai I, Chaigneau L. Humeral metastasis as the only recurrence of a 5-year resected gastrointestinal stromal tumor: a case report. J Med Case Rep 2021; 15:428. [PMID: 34404447 PMCID: PMC8371842 DOI: 10.1186/s13256-021-02962-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 06/16/2021] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Gastrointestinal stromal tumors represent the most frequently encountered primary mesenchymal tumors. Whereas the liver and the peritoneum are known to be the preferential metastasis sites, no therapeutic standard has yet been established for the management of bone metastases because of their very low incidence. We report a unique example of a single humerus metastasis of a jejunal gastrointestinal stromal tumor. CASE PRESENTATION We report the case of a 72-year-old European woman whose jejunal gastrointestinal stromal tumor was resected in 2013 and treated during the following 3 years with imatinib (400 mg daily). In 2018, she developed a single humeral bone lesion that was identified as a gastrointestinal stromal tumor metastasis. After 7 months of imatinib intake, reconstructive surgery was performed. Pathologists confirmed the satisfactory histological regression and assessed the complete tumor resection. The patient is still on imatinib maintenance therapy, with no recurrence reported so far. She fully recovered the upper limb function after following an appropriate rehabilitation program. DISCUSSION Current literature and published case reports indicate that bones are one of the rarest locations of gastrointestinal stromal tumor metastasis (about 1%), with occurrence mainly in the spine. Patients initially diagnosed with gastrointestinal stromal tumor of the small intestine and stomach are more likely to suffer from bone metastasis, compared with other gastrointestinal stromal tumor locations. The median overall survival rate is higher for patients with isolated bone metastasis compared with those having liver metastasis. Metastasis occurs on average 4 years after the primary, but it may take up to 20 years, emphasizing the need for long-term clinical and radiological monitoring. Although specific guidelines for such cases have not yet been established, we suggest that a multimodal concerted approach involving surgery or radiotherapy associated with tyrosine kinase inhibitor intake should be considered. CONCLUSION Bones are one of the rarest locations of gastrointestinal stromal tumor metastasis. A multidisciplinary collaboration was set up to allow conservative surgery of our patient after several months of imatinib treatment. A year and a half later, the patient is still in complete remission. This specific case supports the concept of an intermediate stage between local and oligometastatic disease that should be managed with a curative aim, as much as possible.
Collapse
Affiliation(s)
- C. Braunstein
- Service d’Anatomie Pathologique, Hôpital Nord Franche-Comté, Trévenans, France
| | - F. Sirveaux
- Service de Chirurgie Orthopédique, Centre Hospitalo-Universitaire de Nancy, Laxou, France
| | - E. Kalbacher
- Service d’Oncologie Médicale, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| | - S. Aubry
- Service de Radiologie et d’imagerie Médicale, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| | - D. Delroeux
- Centre de Chirurgie Viscérale, Clinique St-Vincent, Besançon, France
| | - P. Hubert
- Service d’Oncologie Médicale, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| | - B. Marie
- Service d’Anatomie et Cytologie Pathologiques, Centre Hospitalo-Universitaire de Nancy, Laxou, France
| | - G. Meynard
- Service d’Oncologie Médicale, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| | - I. Mihai
- Service d’Anatomie et Cytologie Pathologique, Hôpital Nord Franche-Comté, Trévenans, France
| | - L. Chaigneau
- Service d’Oncologie Médicale, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| |
Collapse
|
7
|
Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. Eur J Cancer 2021; 150:1-9. [PMID: 33882374 PMCID: PMC7997727 DOI: 10.1016/j.ejca.2021.03.033] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 03/09/2021] [Accepted: 03/18/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus. METHODS We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients. RESULTS In this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in patients without a cancer history (n = 29). However, our results highlight a lack in the generation of T-cell responses against CoV-N, M and S proteins from the SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses were not hampered in cancer patients. CONCLUSION Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs.
Collapse
Affiliation(s)
- Laura Mansi
- Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France.
| | - Laurie Spehner
- Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France
| | - Etienne Daguindau
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Hematology, University Hospital of Besancon, France
| | - Kevin Bouiller
- Department of Infectious Disease, University Hospital of Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000, Besançon, France
| | - Hamadi Almotlak
- Department of Medical Oncology, University Hospital of Besançon, France
| | - Ulrich Stein
- Department of Medical Oncology, University Hospital of Besançon, France
| | - Adeline Bouard
- Department of Hematology, University Hospital of Besancon, France
| | - Stefano Kim
- Department of Medical Oncology, University Hospital of Besançon, France
| | - Elodie Klajer
- Department of Medical Oncology, University Hospital of Besançon, France
| | - Marine Jary
- Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France
| | - Guillaume Meynard
- Department of Medical Oncology, University Hospital of Besançon, France
| | - Angélique Vienot
- Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France
| | - Charlée Nardin
- Department of Dermatology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France
| | - Fernando Bazan
- Department of Medical Oncology, University Hospital of Besançon, France
| | - Quentin Lepiller
- Department of Virology, University Hospital of Besançon, France; Research Unit EA3181, Université de Franche Comté, F-25000 Besançon, France
| | - Virginie Westeel
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Pneumology, University Hospital of Besancon, France
| | - Olivier Adotévi
- Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France
| | - Christophe Borg
- Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France
| | - Marie Kroemer
- INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France; Department of Pharmacy, University Hospital of Besançon, France
| |
Collapse
|
8
|
Dairain A, Maire O, Meynard G, Richard A, Rodolfo-Damiano T, Orvain F. Sediment stability: can we disentangle the effect of bioturbating species on sediment erodibility from their impact on sediment roughness? Mar Environ Res 2020; 162:105147. [PMID: 33027713 DOI: 10.1016/j.marenvres.2020.105147] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 09/04/2020] [Accepted: 09/06/2020] [Indexed: 06/11/2023]
Abstract
Benthic organisms, in particular bioturbators, can influence erosion processes either by affecting sediment roughness through their mere presence and/or activities, or by modulating sediment characteristics (e.g., silt content, granulometry), thus altering its erodibility. To date, it was not possible to distinguish the influence of bioturbating species on sediment roughness from their impact on sediment erodibility. Consequently, uncertainties remain regarding the role played by benthic species on sediment dynamics. In this study, we used a canal flume which allows to record the bed shear stress at the surface of a non-cohesive sediment (4% of mud) during erosion experiments, thus allowing to disentangle the influence of bioturbators, here the common cockle Cerastoderma edule, on the two erosion mechanisms. In order to assess the influence of bioturbators on sediment stability in different environmental situations, we additionally tested for the effects of three factors, i.e. bivalve density, availability of suspended food (i.e. phytoplankton presence) and microphytobenthos (MPB) occurrence, which may modulate the behavior of cockles. We observed that cockles promote the erosion of the sediment surficial layer by increasing its roughness as a consequence of their sediment reworking activity and/or presence at the sediment surface (emerging shell). In contrast, we calculated similar critical bed shear stress for erosion with and without bivalves suggesting that cockles have a minor influence on the erodibility of non-cohesive substrates with a low silt content. The destabilizing effect of cockles increased with the bivalve density whereas it was attenuated by the presence of phytoplankton. We hypothesize that the magnitude of cockles' bioturbation activity was lower when a high proportion of suspended food is available. High concentrations of suspended food may also have enhanced the filtration and biodeposition rates of cockles, thus rapidly leading to the 'muddification' of the sediment bed and consequently counteracting with the own destabilizing effect of the bivalves. Finally, the sole presence of MPB did not significantly affect the resuspension dynamics of non-cohesive sediments with a low proportion of mud.
Collapse
Affiliation(s)
- Annabelle Dairain
- Unité Biologie des ORganismes et Ecosystèmes Aquatiques (FRE BOREA), Sorbonne Universités, Muséum National d'Histoire Naturelle, CNRS, Université Pierre et Marie Curie, Université de Caen Normandie, IRD 207, Université des Antilles, Esplanade de la paix, F-14032, Caen, France; Marine Biology Research Group, Department of Biology, Ghent University, Krijgslaan 281/S8, Ghent, 9000, Belgium.
| | - Olivier Maire
- Univ. Bordeaux, CNRS, EPOC, EPHE, UMR 5805, F-33600, Pessac, France
| | - Guillaume Meynard
- Unité Biologie des ORganismes et Ecosystèmes Aquatiques (FRE BOREA), Sorbonne Universités, Muséum National d'Histoire Naturelle, CNRS, Université Pierre et Marie Curie, Université de Caen Normandie, IRD 207, Université des Antilles, Esplanade de la paix, F-14032, Caen, France
| | - Anaïs Richard
- Univ. Bordeaux, CNRS, EPOC, EPHE, UMR 5805, F-33600, Pessac, France
| | | | - Francis Orvain
- Unité Biologie des ORganismes et Ecosystèmes Aquatiques (FRE BOREA), Sorbonne Universités, Muséum National d'Histoire Naturelle, CNRS, Université Pierre et Marie Curie, Université de Caen Normandie, IRD 207, Université des Antilles, Esplanade de la paix, F-14032, Caen, France
| |
Collapse
|
9
|
Dairain A, Maire O, Meynard G, Orvain F. Does parasitism influence sediment stability? Evaluation of trait-mediated effects of the trematode Bucephalus minimus on the key role of cockles Cerastoderma edule in sediment erosion dynamics. Sci Total Environ 2020; 733:139307. [PMID: 32454293 DOI: 10.1016/j.scitotenv.2020.139307] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Revised: 03/28/2020] [Accepted: 05/07/2020] [Indexed: 06/11/2023]
Abstract
In coastal environments, bioturbators greatly influence the physical and biogeochemical properties of sediments with consequences for central ecological processes such as erosion dynamics. In addition to their direct impact on sediment stability, bioturbators can have an impact on sediment erosion processes by modulating the growth of microphytobenthic organisms that stabilise the surface layer of sediments. The direct and indirect influences of bioturbators on sediment dynamics depend on the magnitude of their activity and inherently on their physiological state. Bioturbators are infected by various parasites, which have a substantial impact on their physiology and behaviour. However, the knock-on effects of parasites on key ecosystem functions like sediment dynamics remain poorly studied. We conducted flume experiments to investigate the indirect influence of the trematode Bucephalus minimus parasitising the common cockle Cerastoderma edule on the dynamics of sandy sediments enriched or not with microphytobenthos (MPB). Cockles modified bed roughness, sediment surface erodibility and hence destabilised sandy sediments. In sediments not enriched with MPB, both unparasitised and parasitised organisms had a similar impact on the stability of sandy sediments. In contrast, parasitism slightly reduced the destabilisation effect of cockles in MPB-enriched sediments. In the latter, parasitised cockles did not interfere with MPB growth whereas unparasitised organisms constrained the microalgae development. However, the enrichment of the surface layers of sandy sediments with MPB did not modulate the erosion dynamics of these environments. Thus, the lower destabilisation effect of parasitised cockles was not here linked to a stabilisation effect of MPB. When standardised for length, parasitised cockles were lighter than unparasitised organisms. Weakened cockles may have had a lower bioturbation potential than unparasitised conspecifics. If so, the influence parasitised cockles had on sediment erodibility and sediment roughness may have been reduced. The absence of a parasitism effect on the dynamics of MPB-unenriched sediments remains nonetheless unclear.
Collapse
Affiliation(s)
- Annabelle Dairain
- Unité Biologie des ORganismes et Ecosystèmes Aquatiques (FRE 2030 BOREA), Sorbonne Université, Muséum National d'Histoire Naturelle, CNRS, Université Pierre et Marie Curie, Université de Caen Normandie, IRD 207, Université des Antilles, Esplanade de la paix, F-14032, Caen, France.
| | - Olivier Maire
- Univ. Bordeaux, EPOC, UMR CNRS 5805, F-33400 Talence, France
| | - Guillaume Meynard
- Unité Biologie des ORganismes et Ecosystèmes Aquatiques (FRE 2030 BOREA), Sorbonne Université, Muséum National d'Histoire Naturelle, CNRS, Université Pierre et Marie Curie, Université de Caen Normandie, IRD 207, Université des Antilles, Esplanade de la paix, F-14032, Caen, France
| | - Francis Orvain
- Unité Biologie des ORganismes et Ecosystèmes Aquatiques (FRE 2030 BOREA), Sorbonne Université, Muséum National d'Histoire Naturelle, CNRS, Université Pierre et Marie Curie, Université de Caen Normandie, IRD 207, Université des Antilles, Esplanade de la paix, F-14032, Caen, France
| |
Collapse
|
10
|
Bazan F, Dobi E, Royer B, Curtit E, Mansi L, Menneveau N, Paillard MJ, Meynard G, Villanueva C, Pivot X, Chaigneau L. Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer. BMC Cancer 2019; 19:1029. [PMID: 31675937 PMCID: PMC6823971 DOI: 10.1186/s12885-019-6228-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 10/09/2019] [Indexed: 01/06/2023] Open
Abstract
Background Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patients with central nervous system (CNS) metastases of breast cancer. Methods Twenty-two patients with CNS metastases treated by MTX (3 g/m2) between April 2004 and October 2009 were enrolled. Clinical response rate, time to progression (TTP), overall survival (OS), and safety were assessed. Results In terms of brain metastases, 2 patients (9%) achieved a partial response, 10 patients (45%) had disease stabilization, and 10 patients (45%) had disease progression. In others metastatic sites, 7 patients (39%) achieved a disease stabilization, and 11 patients (61%) had disease progression. TTP and OS were 2.1 (95%CI 1.4–2.9) and 6.3 (95%CI 1.8–10) months, respectively. Conclusion High-dose MTX demonstrated a moderate activity at 3 g/m2. Nonetheless, the favorable toxicity profile should suggest the possibility to increase the dosage and further study are planned.
Collapse
Affiliation(s)
- F Bazan
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - E Dobi
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - B Royer
- Department of Clinical Pharmacology and Toxicology, University Hospital of Besancon, Besancon, France
| | - E Curtit
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - L Mansi
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - N Menneveau
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - M J Paillard
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - G Meynard
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France
| | - C Villanueva
- Centre de Cancérologie du grand Montpellier, Montpellier, France
| | - X Pivot
- Centre Paul Strauss, Porte de l'Hopital Strasbourg, Strasbourg, France
| | - L Chaigneau
- Department of Medical Oncology, University Hospital of Besancon, Besancon, France. .,Department of Medical Oncology, University Hospital Jean Minjoz, Boulevard Alexandre Fleming, F-25000, Besancon, France.
| |
Collapse
|
11
|
Curtit E, Bazan F, Chaigneau L, Mouillet G, Dobi E, Mansi L, Meneveau N, Paillard MJ, Meynard G, Klajer E, Villanueva C, Montcuquet P, Pivot X, Cals L. Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.347] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Klajer E, Paget-Bailly S, Meynard G, Meurisse A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Montcuquet P, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Populaire C, Collonge-Rame MA, Gligorov J, Curtit E, Pivot X, Mansi L. Impact of BRCA status on outcomes and survival in high-risk early breast cancers. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy270.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A. [DNA damage repair: An emerging strategy in metastatic prostate cancer]. Bull Cancer 2018; 105:944-954. [PMID: 30278883 DOI: 10.1016/j.bulcan.2018.05.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2018] [Accepted: 05/25/2018] [Indexed: 12/17/2022]
Abstract
Genetic instability is one part of the oncogenic process. Gene mutations involved in DNA repair mechanisms can promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, DNA repair abnormalities mainly correspond to somatic or constitutional mutations of the BRCA2 and ATM genes. Therapeutic management of metastatic castration-resistant prostate cancer (mCRPC) is currently based on new hormonal therapies (abiraterone, enzalutamide) and taxane-type chemotherapy (docetaxel or cabazitaxel). Preliminary data tend to indicate a specific activity of agents causing DNA breaks (platinum salts) and PARP inhibitors in patients with these DNA repair abnormalities. The frequency of DNA repair gene mutations in patients with prostate cancer (around 20%) and the antitumor response of PARP inhibitors make it a possible short-term therapeutic strategy with several registering clinical trials ongoing.
Collapse
Affiliation(s)
- Yohann Loriot
- Gustave-Roussy, département de médecine, Inserm U981, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | | | - Elodie Klajer
- CHU de Besançon, oncologie, 25030 Besançon cedex, France
| | | | - Noémie Gassian
- CHU de Besançon, oncologie, 25030 Besançon cedex, France
| | - Antoine Thiery-Vuillemin
- CHU de Besançon, oncologie, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon, France.
| |
Collapse
|
14
|
Meynard G, Boullerot L, Belmiloudi S, Dosset M, Laheurte C, Guenat D, Rangan L, Lauret Marie Joseph E, Verlut C, Godet Y, Valmary-Degano S, Mihai I, Pivot X, Curtit E, Adotevi O. Presence of naturally occurring anti-telomerase CD4 Th1 immunity in glioblastoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Meynard G, Mansi L, Lebahar P, Villanueva C, Klajer E, Calcagno F, Vivalta A, Chaix M, Collonge-Rame MA, Populaire C, Algros MP, Colpart P, Neidich J, Pivot X, Curtit E. First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report. Oncol Rep 2017; 37:1573-1578. [DOI: 10.3892/or.2017.5422] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 01/02/2017] [Indexed: 11/06/2022] Open
|
16
|
Curtit E, Meynard G, Villanueva C, Mansi L, Chaix M, Vilalta A, Kuo JZ, Villa M, Neidich J, Tomar A, Arianpour A, Lebahar P, Pivot X. Abstract P2-09-10: Double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-09-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Double heterozygosity is an extremely rare occurrence in hereditary breast and ovarian cancer syndrome (HBOC [MIM 604370; MIM 612555]) where two pathogenic variants, one in BRCA1 and one in BRCA2, are found in an individual. To date, only a few case reports and case series have been reported in the literature (1-3). Furthermore, little is known about the clinical characteristics, family history, and tumor histology in these patients. In this study, we utilized targeted gene testing with next-generation sequencing (NGS) technology in an early-onset metastatic breast cancer patient from France. We evaluated germline variants using Pathway Genomics' BRCATrueTM NGS test, which analyzes variants covering all exons and exon flanking regions in both the BRCA1 and BRCA2 genes. All variant calls were determined after alignment and mapping to the GRCh37/hg19 reference genome. Variant calls were confirmed by Sanger sequencing. In this patient, a c.1016dupA (p.V340GfsX6) frameshift variant was found in BRCA1 along with a c.6814delA (p.R2272EfsX8) frameshift variant in BRCA2. Both frameshift variants are predicted to truncate the BRCA proteins. The BRCA1 c.1016dupA variant is considered a Norwegian founder mutation but has also been observed in individuals who are of French-Canadian, French, Italian or Dutch ancestry (4-7). The BRCA2 c.6814delA (p.R2272Efs*8) pathogenic variant, also known as 7042delA, is predicted to truncate the BRCA2 protein and has been identified in individuals with a personal or family history of breast and/or ovarian cancer (8,9). To the best of our knowledge, the combination of these two pathogenic variants in an individual has not been previously reported. In a clinical diagnostic setting, the possibility of double heterozygosity of pathogenic variants in more than one susceptibility gene should be considered, especially in patients with early-onset metastatic cancers. Furthermore, genetic testing and genetic counseling should also be indicated for high-risk family members.
1. Heidemann, S. et al. (2012) Breast cancer research and treatment 134, 1229-1239
2. Lavie, O., et al. (2011) Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 22, 964-966
3. Nomizu, T., et al. (2012). Breast cancer
4. Andersen, T. I., Borresen, A. L., and Moller, P. (1996) American journal of human genetics 59, 486-487
5. Caputo, S., et al. (2012) Nucleic acids research 40, D992-1002
6. Dorum, A., et al. (1999). American journal of human genetics 65, 671-679
7. Simard, J., et al. (1994). Nature genetics 8, 392-398
8. Novakovic, S., et al. (2012) International journal of oncology 41, 1619-1627
9. Tea, M. K., et al. (2014) Maturitas 77, 68-72.
Citation Format: Curtit E, Meynard G, Villanueva C, Mansi L, Chaix M, Vilalta A, Kuo JZ, Villa M, Neidich J, Tomar A, Arianpour A, Lebahar P, Pivot X. Double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-10.
Collapse
Affiliation(s)
- E Curtit
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - G Meynard
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - C Villanueva
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - L Mansi
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - M Chaix
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - A Vilalta
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - JZ Kuo
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - M Villa
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - J Neidich
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - A Tomar
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - A Arianpour
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - P Lebahar
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| | - X Pivot
- Service Oncologie Médicale-CHU Besançon, Besançon, Cédex, France; Pathway Genomics, San Diego, CA
| |
Collapse
|
17
|
Ducassou D, Leccia F, Bonichon F, Meynard G. [Scintigraphy using Technetium 99 m pyrophosphate in detection of bone metastasis of breast cancers. Analysis of 310 examinations]. Nouv Presse Med 1977; 6:1729-32. [PMID: 194221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Three hundred and ten bone scintigraphies were carried out in patients with a carcinoma of the breast. The results of these studies were compared not only with radiological findings but also the clinical and paraclinical course of the patients, the period of observation being between 8 and 44 months. Amongst the scintigrams in which no abnormality was detected, approximately 3.3% were obtained in patients with osteolytic metastases, the majority of these patients also having a rapidly growing primary tumourmamongst the patients with zones of hyperfixation and, at the same time, non-fixing metastases, 14/22 diedvery rapidly with diffuse bone metastases, this confirming the notion of poor prognosis in this "false negative" group. 11.3% of the abnormal results involved patients who showed no bone lesions more than 6 months after radio-isotopic examination "false positives". Of these, 12/18 were single lessions (41%). 14% of examinations carried out on a routine basis demonstrated metastases for which clinical and/or radiological confirmation was obtained only 2 to 9 months later.
Collapse
|